Aliases & Classifications for Burns

Summaries for Burns

MedlinePlus : 41 a burn is damage to your body's tissues caused by heat, chemicals, electricity, sunlight, or radiation. scalds from hot liquids and steam, building fires and flammable liquids and gases are the most common causes of burns. another kind is an inhalation injury, caused by breathing smoke. there are three types of burns: first-degree burns damage only the outer layer of skin second-degree burns damage the outer layer and the layer underneath third-degree burns damage or destroy the deepest layer of skin and tissues underneath burns can cause swelling, blistering, scarring and, in serious cases, shock, and even death. they also can lead to infections because they damage your skin's protective barrier. treatment for burns depends on the cause of the burn, how deep it is, and how much of the body it covers. antibiotic creams can prevent or treat infections. for more serious burns, treatment may be needed to clean the wound, replace the skin, and make sure the patient has enough fluids and nutrition. nih: national institute of general medical sciences

MalaCards based summary : Burns is related to dracunculiasis and keloids. An important gene associated with Burns is TTR (Transthyretin), and among its related pathways/superpathways are Insulin secretion and IL-17 Family Signaling Pathways. The drugs silver nitrate and Bacitracin have been mentioned in the context of this disorder. Affiliated tissues include Umbilical Cord, skin and eye, and related phenotypes are Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) and hematopoietic system

Related Diseases for Burns

Diseases related to Burns via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 558)
id Related Disease Score Top Affiliating Genes
1 dracunculiasis 30.7 INS TNF
2 keloids 29.7 IL1B TNF
3 euthyroid sick syndrome 29.6 CRH TNF
4 lymphoma 29.0 ALB IL1B TNF
5 bullous skin disease 28.9 CSF2 IL1B TNF
6 scabies 28.7 ALB IL1B TNF
7 calcinosis 28.1 ALB CRH INS TNF
8 hypertrichosis 27.5 ALB IL1B INS TNF
9 burning mouth syndrome 12.3
10 burn-mckeown syndrome 12.2
11 burn scar 11.9
12 partial deep dermal and full thickness burns 11.9
13 burning mouth syndrome type 3 11.8
14 burn goodship syndrome 11.7
15 choanal atresia-hearing loss-cardiac defects-craniofacial dysmorphism syndrome 11.2
16 orofaciodigital syndrome iv 11.2
17 complex regional pain syndrome 11.1
18 glossodynia 11.1
19 trigeminal neuralgia 11.1
20 herpes zoster 11.0
21 reflex sympathetic dystrophy 11.0
22 erythromelalgia 11.0
23 paresthesia 11.0
24 causalgia 11.0
25 polyneuropathy 11.0
26 fabry disease 11.0
27 hypertrophic scars 10.9
28 mental retardation, x-linked, syndromic 13 10.9
29 lichen planus 10.9
30 oral submucous fibrosis 10.8
31 cellulitis 10.8
32 glossitis 10.8
33 hypothyroidism 10.8
34 zygomycosis 10.8
35 eczema herpeticum 10.8
36 geographic tongue 10.8
37 conjunctivitis 10.8
38 central pontine myelinolysis 10.8
39 chronic pain 10.8
40 restless legs syndrome 10.8
41 erythermalgia, primary 10.8
42 vaginitis 10.7
43 central pain syndrome 10.7
44 papilledema 10.6 TNF TTR
45 peripheral nervous system disease 10.6
46 arachnoiditis 10.6
47 tetanus 10.6
48 meralgia paresthetica 10.6
49 mercury poisoning 10.6
50 peptic ulcer disease 10.6

Graphical network of the top 20 diseases related to Burns:



Diseases related to Burns

Symptoms & Phenotypes for Burns

GenomeRNAi Phenotypes related to Burns according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) GR00104-A-0 8.8 CSF2 INS TNF

MGI Mouse Phenotypes related to Burns:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.87 CRH CSF2 HGF IL1B INS SERPINC1
2 homeostasis/metabolism MP:0005376 9.86 ALB CRH CSF2 IL1B INS SERPINC1
3 liver/biliary system MP:0005370 9.63 ALB CRH HGF INS SERPINC1 TNF
4 no phenotypic analysis MP:0003012 9.35 CRH HGF INS TNF TTR
5 renal/urinary system MP:0005367 9.02 ALB CRH CSF2 INS SERPINC1

Drugs & Therapeutics for Burns

Drugs for Burns (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 840)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1 silver nitrate Approved Phase 4,Phase 3,Phase 2
2
Bacitracin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 1405-87-4 439542 10909430
3
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-23-7 5754 657311
4
Carboprost Tromethamine Approved Phase 4 58551-69-2 5284525 45266502
5
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 1 76631-46-4, 113775-47-6 68602 5311068 56032
6
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 437-38-7 3345
7
Chlorhexidine Approved, Vet_approved Phase 4,Phase 3,Phase 1 55-56-1 9552079 2713
8
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 22916-47-8 4189
9
Aminolevulinic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 106-60-5 137
10
Donepezil Approved Phase 4,Phase 3 120014-06-4 3152
11
Midazolam Approved, Illicit Phase 4,Phase 2 59467-70-8 4192
12
Remifentanil Approved Phase 4 132875-61-7 60815
13
Silver sulfadiazine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 22199-08-2 441244
14
Sulfadiazine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 68-35-9 5215
15
Benzocaine Approved Phase 4,Phase 3,Phase 2,Early Phase 1 1994-09-7, 94-09-7 2337
16
Benzoyl peroxide Approved Phase 4,Phase 3,Phase 2,Phase 1 94-36-0 7187
17
Pioglitazone Approved, Investigational Phase 4,Phase 2,Phase 3 111025-46-8 4829
18
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 2 9004-61-9 53477741 24759
19
Ephedrine Approved Phase 4,Phase 3,Phase 1 299-42-3 9294
20
Pseudoephedrine Approved Phase 4,Phase 3,Phase 1 90-82-4 7028
21
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 124-94-7 31307
22
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2 75614-87-8, 51-45-6 774
23
Hydrogen peroxide Approved, Vet_approved Phase 4 7722-84-1 784
24
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 564-25-0 54671203
25
Ethanol Approved Phase 4,Phase 3,Phase 1,Early Phase 1 64-17-5 702
26
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
27
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-02-2 5743
28 Povidone-iodine Approved Phase 4 25655-41-8
29
Petrolatum Approved Phase 4,Phase 3,Phase 2 8009-03-8
30
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
31
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 137-58-6 3676
32
Epinephrine Approved, Vet_approved Phase 4,Phase 1,Early Phase 1 51-43-4 5816
33 Racepinephrine Approved Phase 4,Phase 1,Early Phase 1
34
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 1 83-43-2 6741
35
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 1 50-24-8 5755
36
Thrombin Approved Phase 4,Phase 2,Phase 3,Phase 1
37
Capsaicin Approved Phase 4,Phase 1,Phase 2 404-86-4 1548943
38
Azelaic acid Approved Phase 4 123-99-9 2266
39
Metronidazole Approved Phase 4,Phase 3 443-48-1 4173
40
Sertraline Approved Phase 4 79617-96-2 68617
41
Adapalene Approved Phase 4,Phase 3,Phase 1,Phase 2 106685-40-9 60164
42
Leuprolide Approved, Investigational Phase 4 53714-56-0 3911 657181
43
Magnesium Sulfate Approved, Vet_approved Phase 4 7487-88-9 24083
44
Penciclovir Approved Phase 4 39809-25-1 4725
45
Guaifenesin Approved, Vet_approved Phase 4,Phase 3 93-14-1 3516
46
Ketamine Approved, Vet_approved Phase 4,Phase 3,Phase 2 6740-88-1 3821
47
Methadone Approved Phase 4 76-99-3 4095
48
Desloratadine Approved, Investigational Phase 4 100643-71-8 124087
49
Loratadine Approved Phase 4,Phase 3,Phase 2 79794-75-5 3957
50
Ticlopidine Approved Phase 4 55142-85-3 5472

Interventional clinical trials:

(show top 50) (show all 1407)

id Name Status NCT ID Phase Drugs
1 Hypoalbuminemia in Burn Patients Unknown status NCT01436292 Phase 4 5% human albumin solution (HAS)
2 Early Fluid Resuscitation With Balanced HES 130/0.4 [6%] in Severe Burn Injury Unknown status NCT01012648 Phase 4 Fluid resuscitation;HES 130/0.4 (6%), Voluven balanced vs. Lactated Ringer's solution
3 Fluid Shifts During Resuscitation: Impacts on Macrocirculation and Microcirculation Unknown status NCT00326729 Phase 4
4 Computerized Counseling to Promote Positive Prevention and HIV Health in Kenya Unknown status NCT01015989 Phase 4
5 The Treatment of Bartholin´s Cyst or Abscess With Silver Nitrate Unknown status NCT00786461 Phase 4
6 Clinical Evaluation of T.R.U.E. Test Allergens in Children an Adolescents Unknown status NCT01797562 Phase 4 T.R.U.E. Test Panel 3.2
7 Evaluate the Efficacy, Safety and Tolerability of a Non-hormonal Intravaginal Gel in Postmenopausal Women With Symptoms of Vaginal Dryness. Unknown status NCT02571127 Phase 4 Hidra1
8 Dexmedetomidine on Prevention of Side Effects of Hemabate Unknown status NCT02220361 Phase 4 placebo;low dose dexmedetomidine;high dose dexmedetomidine
9 Intranasal Fentanyl for Pain Management Unknown status NCT00882960 Phase 4 intravenous fentanyl;intra-nasal fentanyl
10 Oral Nutrition Impact on Tear Film Unknown status NCT01561040 Phase 4
11 Trial on the Efficacy of Tegaderm Chlorhexidine Gluconate (CHG) in Reducing Catheter Related Bloodstream Infections Unknown status NCT01142934 Phase 4
12 Effect of Fluticasone Proprionate 0.05% on Narrow Band UV-B in Active Vitiligo Unknown status NCT01246921 Phase 4 Fluticasone proprionate 0.05% cream
13 Superficial Basal Cell Carcinoma Treatment With Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage Methylaminolevulinate Unknown status NCT01491711 Phase 4 Methylaminolevulinate PDT in 2 sessions;Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT
14 CALM-AD Unknown status NCT00142324 Phase 4 Donepezil
15 The Effect of High-dose Remifentanil on Established Sunburn-induced Hyperalgesia in Human Volunteers (HighDose RemiSun) Unknown status NCT01015482 Phase 4 Remifentanil;Midazolam
16 The Effect of Remifentanil on Established Sunburn-induced Hyperalgesia in Human Volunteers Unknown status NCT00811837 Phase 4 Midazolam;Remifentanil
17 Treatment of Facial Burns With Flammacerium Compared to Flammazine and the Impact of Facial Burns on Psychosocial Wellbeing Completed NCT00297752 Phase 4 ceriumnitrate silversulfadiazine (flammacerium);silversulfadiazine (flammazine)
18 The Effect of Two Versus Ten Days Application of Flammacerium in Partial Thickness Burns Completed NCT00156988 Phase 4 cerium nitrate-silver sulfadiazine (cerium-flamazine)
19 An Open, Randomized, Multi-centre Investigation With Mepilex Ag Versus Silver Sulfadiazine in the Treatment of Deep Partial Thickness Burn Injuries. Completed NCT01439074 Phase 4 Silver sulphadiazine
20 Pharmacokinetics Ertapenem Burns Completed NCT01497990 Phase 4 Ertapenem
21 Efficacy and Safety Study of rhGM-CSF Gel to Treat Deep 2nd Thickness Burn Completed NCT01785784 Phase 4 rhGM-CSF Gel
22 Comparative Analysis of Cost-effectiveness of Silver Dressing in Burns Completed NCT02108535 Phase 4 Nanocrystalline silver;Silver Sulphadiazine
23 Comparison of Wound Bed Establishment in Facial Burns Completed NCT01668030 Phase 4 Enzymatic agent;Bacitracin
24 Evaluation of Post Burn Rehabilitation Population for Itch Control Completed NCT00782054 Phase 4
25 Continuous Lidocaine Infusion for Management of Perioperative Burn Pain Completed NCT02059902 Phase 4 Lidocaine
26 Comparison of a Water-soluble Topical Antimicrobial to Silver Sulfadiazine in Partial Thickness Burns Completed NCT01926392 Phase 4 water-soluble therapy;silver sulfadiazine
27 Effect of Early Enteral Tube Feeding Nutrition With an Immune Enhancing Diet in Severe Burn Patients Completed NCT00561210 Phase 4
28 An Acellular Epithelial Skin Substitute in Deep Partial-thickness Burns Completed NCT01454310 Phase 4
29 Low-dose Hydrocortisone in Acutely Burned Patients Completed NCT00149123 Phase 4 hydrocortisone 200 mg/day
30 Caustic Esophageal Burns in Children and High Doses of Methylprednisolone Completed NCT02002078 Phase 4 methylprednisolon
31 Evaluating the Cost-effectiveness, Efficacy, Safety and Tolerance of Mepilex® Ag Versus Silvadene® Completed NCT00742183 Phase 4
32 Safety and Immunogenicity Study of Recombinant Thrombin (rThrombin) in Pediatric Participants Completed NCT00859547 Phase 4
33 Open, Prosp, Rand. Invest. Evaluating Pain With Mepitel One vs.Bridal Veil and Staples on Split Thickness Skin Grafts Completed NCT01365273 Phase 4
34 Treatment of Wounds With a New Adhesive Foam Dressing Completed NCT02807584 Phase 4
35 Hemostatic Textile to Control Bleeding at Donor Graft Sites Completed NCT00855569 Phase 4
36 Ethnic Differences in Response to Topical Capsaicin: A Psychophysical Study on Healthy Subjects Completed NCT00655811 Phase 4 Capsaicin;Placebo moisturizing cream
37 Split-face Tolerability Comparison Between MetroGel® 1% vs Finacea® 15% in Subjects With Healthy Skin Completed NCT01139047 Phase 4 metronidazole 1% gel;azelaic acid 15% gel
38 Split-Face Tolerability Comparison Between MetroGel® 1% Versus Finacea® 15% in Subjects With Healthy Skin Completed NCT01139008 Phase 4 metronidazole 1% gel;azelaic acid 15% gel
39 A Study of Sertraline to Prevent PTSD Completed NCT00182078 Phase 4 Placebo;Sertraline
40 Aruba Aloe Formula F-BC-096 in the Treatment of Split Thickness Donor Site After Wound Closure Completed NCT01213420 Phase 4
41 Split-face Tolerability Comparison Between Adapalene-Benzoyl Peroxide Gel Versus Tretinoin Gel Completed NCT01522456 Phase 4 Epiduo Gel;Retin-A Micro Microsphere 0.1%
42 "TAKE TIME" Pioglitazone Reverses Defects in Mitochondrial Biogenesis in Patients With T2DM Completed NCT00402012 Phase 4 Pioglitazone
43 Safety Study of Cosmetic Tissue Augmentation in People of Color Completed NCT01147172 Phase 4
44 Randomized Trial of Two Ablation Catheters in Paroxysmal Atrial Fibrillation Completed NCT00678340 Phase 4
45 Effect of Topically-Applied Hyaluronic-Acid on Palatal Epithelial Wound Closure Completed NCT02534415 Phase 4 Periodontal dressing material;0.2% Hyaluronic acid gel;0.8% Hyaluronic acid gel
46 Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration Completed NCT01161563 Phase 4 Triptorelin pamoate;Leuprolide acetate
47 Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye Completed NCT01488396 Phase 4 0.05%cyclosporin eye drop
48 A Clinical Trial to Study the Effects of Two Drugs, Lycopene and Prednisolone in Patients With Oral Lichen Planus Completed NCT02587117 Phase 4 lycopene;Prednisolone
49 The Effect of Consuming a guaraná and Vitamin/Mineral Complex Pre-exercise on Affect, Exertion, Metabolism and Cognition Completed NCT01929694 Phase 4
50 Evaluation of Irritation by Two Facial Gels Applied to Opposite Sides of the Face Completed NCT00919191 Phase 4 Tretinoin gel;Adapalene and Benzoyl peroxide

Search NIH Clinical Center for Burns

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Burns cell therapies at LifeMap Discovery.

Genetic Tests for Burns

Anatomical Context for Burns

MalaCards organs/tissues related to Burns:

39
Skin, Eye, Testes, Breast, Lung, Brain, Spinal Cord
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Burns:
id Tissue Anatomical CompartmentCell Relevance
1 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate

Publications for Burns

Articles related to Burns:

(show top 50) (show all 2304)
id Title Authors Year
1
Peripheral Neuropathy and Nerve Compression Syndromes in Burns. ( 28888304 )
2017
2
People with Borderline Personality Disorder and Burns: Some Considerations for Health Professionals. ( 28945490 )
2017
3
Thyroid Crisis in a Patient With Burn Injury. ( 28157789 )
2017
4
Burning pain: axonal dysfunction in erythromelalgia. ( 28134657 )
2017
5
The Role of Th-17 Cells and I^I' T-Cells in Modulating the Systemic Inflammatory Response to Severe Burn Injury. ( 28368347 )
2017
6
The Use of Dehydrated Human Amnion/Chorion Membranes in the Treatment of Burns and Complex Wounds: Current and Future Applications. ( 28079550 )
2017
7
Modeling Burns for Pre-Cooled Skin Flame Exposure. ( 28880253 )
2017
8
A case-control evaluation of fungiform papillae density in burning mouth syndrome. ( 28833164 )
2017
9
Dressing changes in a burns unit for children under the age of five: A qualitative study of mothers' experiences. ( 28069342 )
2017
10
Current progress in understanding the molecular pathogenesis of burn scar contracture. ( 28546987 )
2017
11
Palisaded Neutrophilic and Granulomatous Dermatitis/Interstitial Granulomatous Dermatitis Overlap: A Striking Clinical and Histologic Presentation With "Burning Rope Sign" and Subsequent Mirror-Image Contralateral Recurrence. ( 28475518 )
2017
12
Burning mouth syndrome. ( 28569120 )
2017
13
"Microbiological findings and antibacterial therapy in Stevens-Johnson syndrome/Toxic Epidermal Necrolysis patients from a Swedish Burn Center". ( 28075032 )
2017
14
Altered structural connectivity of pain-related brain network in burning mouth syndrome-investigation by graph analysis of probabilistic tractography. ( 28361345 )
2017
15
Raising suspicion of maltreatment from burns: Derivation and validation of the BuRN-Tool. ( 28918905 )
2017
16
EXPERIENCE WITH INTEGRAAr AT THE PRAGUE BURNS CENTRE 2002-2016. ( 28869383 )
2017
17
Topical Clonazepam Solution for the Management of Burning Mouth Syndrome: A Retrospective Study. ( 28738111 )
2017
18
Evaluation of scar quality after treatment of superficial burns of the hands and face with Dressilk or Biobrane-An intra-individual comparison. ( 28865837 )
2017
19
Effectiveness of topical silicone gel and pressure garment therapy for burn scar prevention and management in children: study protocol for a randomised controlled trial. ( 28209175 )
2017
20
Burning mouth syndrome: results of screening tests for vitamin and mineral deficiencies, thyroid hormone, and glucose levels-experience at Mayo Clinic over a decade. ( 28436021 )
2017
21
The Significance of Brain Transcranial Sonography in Burning Mouth Syndrome: a Pilot Study. ( 28740270 )
2017
22
THE ROLE OF PROCALCITONIN AS A DIAGNOSTIC MARKER OF BACTERIAL SEPSIS IN BURNS. ( 28876695 )
2017
23
Hyperosmolar metabolic acidosis in burn patients exposed to glycol based topical antimicrobials-A systematic review. ( 28797572 )
2017
24
Effects of low-level laser therapy on burning mouth syndrome. ( 27893167 )
2017
25
Analgesic effect of topical oral capsaicin gel in burning mouth syndrome. ( 28007005 )
2017
26
RF-Burning Mouth Syndrome: New Treatments. ( 27702434 )
2017
27
Perforator-based flaps for the treatment of burn scar contractures: a review. ( 28261622 )
2017
28
Profiling intraoral neuropathic disturbances following lingual nerve injury and in burning mouth syndrome. ( 28330489 )
2017
29
The pedicled groin flap in resurfacing hand burn scar release and other injuries: a five-case series report and review of the literature. ( 28592937 )
2017
30
A diagnostic and therapeutic approach to primary burning mouth syndrome. ( 28916026 )
2017
31
Pain-relieving effects of clonazepam and amitriptyline in burning mouth syndrome: a retrospective study. ( 28473243 )
2017
32
Thermal Burn Scar-Related Squamous Cell Carcinoma in the Eyelid. ( 28221294 )
2017
33
Chronic Orofacial Pain: Burning Mouth Syndrome and Other Neuropathic Disorders. ( 28638895 )
2017
34
Early anticoagulation therapy for severe burns complicated by inhalation injury in a rabbit model. ( 28944866 )
2017
35
The effect of a rehabilitation nursing intervention model on improving the comprehensive health status of patients with hand burns. ( 28062082 )
2017
36
The neck burn scar contracture: a concept of effective treatment. ( 28717655 )
2017
37
Comparison of Salivary Cortisol and I+-amylase Levels and Psychological Profiles in Patients with Burning Mouth Syndrome. ( 28112423 )
2017
38
Does inhalation injury predict mortality in burns patients or require redefinition? ( 28953914 )
2017
39
Identification of causative variants in TXNL4A in Burn-McKeown syndrome and isolated choanal atresia. ( 28905882 )
2017
40
Acalculous Cholecystitis in Burn Patients: Is There a Role for Percutaneous Cholecystostomy? ( 28576245 )
2017
41
CONTINUATION OF FEEDS IN THE UNSTABLE BURNS PATIENT. ( 28876693 )
2017
42
Hypertrophic Burn Scar Research: From Quantitative Assessment to Designing Clinical Sequential Multiple Assignment Randomized Trials. ( 28888317 )
2017
43
A A9burningA9 therapy for burning mouth syndrome: preliminary results with the administration of topical capsaicin. ( 28691458 )
2017
44
Is it SjAPgren's syndrome or burning mouth syndrome? Distinct pathoses with similar oral symptoms. ( 28283095 )
2017
45
Burns Open journal. ( 28089050 )
2017
46
OUR EXPERIENCE WITH THE USE OF 40% BENZOIC ACID FOR NECRECTOMY IN DEEP BURNS. ( 28869382 )
2017
47
Under Pressure: Applying Practice-Based Learning and Improvement to the Treatment of Chronic Neuropathic Pain in Patients with Burns. ( 28888318 )
2017
48
Critical care polyneuropathy in burn injuries: An integrative review. ( 28838678 )
2017
49
Effect of polaprezinc on experimental corrosive esophageal burns in rats. ( 28881910 )
2017
50
Burning mouth syndrome: a systematic review of treatments. ( 28247977 )
2017

Variations for Burns

Expression for Burns

Search GEO for disease gene expression data for Burns.

Pathways for Burns

Pathways related to Burns according to GeneCards Suite gene sharing:

(show all 23)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.19 ALB INS TTR
2
Show member pathways
12.08 CSF2 IL1B TNF
3 11.84 ALB HGF INS
4 11.76 HGF IL1B TNF
5 11.72 CSF2 IL1B TNF
6 11.66 CSF2 IL1B TNF
7 11.64 CSF2 IL1B TNF
8 11.59 CSF2 IL1B TNF
9 11.49 CSF2 IL1B TNF
10
Show member pathways
11.38 CSF2 IL1B TNF
11 11.23 CSF2 IL1B TNF
12
Show member pathways
11.21 CSF2 TNF
13 11.19 HGF IL1B TNF
14 11.14 IL1B TNF
15 11.14 IL1B TNF
16 11.09 IL1B TNF
17 11.08 ALB INS TTR
18 11.07 IL1B TNF
19 10.9 IL1B TNF
20 10.75 IL1B TNF
21 10.72 CSF2 HGF IL1B TNF
22 10.69 CSF2 HGF IL1B TNF
23 10.61 CSF2 IL1B TNF

GO Terms for Burns

Cellular components related to Burns according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 ALB CRH CSF2 HGF IL1B INS
2 extracellular space GO:0005615 9.28 ALB CRH CSF2 HGF IL1B INS

Biological processes related to Burns according to GeneCards Suite gene sharing:

(show all 29)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of protein phosphorylation GO:0001934 9.77 CRH IL1B TNF
2 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.75 IL1B INS TNF
3 cellular protein metabolic process GO:0044267 9.73 ALB INS SERPINC1 TTR
4 activation of MAPK activity GO:0000187 9.71 HGF IL1B TNF
5 positive regulation of cell proliferation GO:0008284 9.71 CRH CSF2 HGF INS
6 protein kinase B signaling GO:0043491 9.64 IL1B TNF
7 lipopolysaccharide-mediated signaling pathway GO:0031663 9.64 IL1B TNF
8 positive regulation of phagocytosis GO:0050766 9.63 IL1B TNF
9 positive regulation of cytokine secretion GO:0050715 9.63 INS TNF
10 positive regulation of cell migration GO:0030335 9.62 HGF INS
11 positive regulation of interleukin-8 production GO:0032757 9.62 IL1B TNF
12 negative regulation of interleukin-6 production GO:0032715 9.61 HGF TNF
13 positive regulation of mitotic nuclear division GO:0045840 9.61 IL1B INS
14 positive regulation of NF-kappaB import into nucleus GO:0042346 9.6 IL1B TNF
15 regulation of protein secretion GO:0050708 9.58 INS TNF
16 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.57 IL1B TNF
17 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 9.56 IL1B TNF
18 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.55 IL1B TNF
19 positive regulation of gene expression GO:0010628 9.55 CRH CSF2 IL1B INS TNF
20 positive regulation of podosome assembly GO:0071803 9.52 CSF2 TNF
21 positive regulation of chemokine biosynthetic process GO:0045080 9.51 IL1B TNF
22 positive regulation of nitric oxide biosynthetic process GO:0045429 9.5 IL1B INS TNF
23 regulation of establishment of endothelial barrier GO:1903140 9.49 IL1B TNF
24 positive regulation of fever generation GO:0031622 9.48 IL1B TNF
25 sequestering of triglyceride GO:0030730 9.46 IL1B TNF
26 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.43 CSF2 IL1B TNF
27 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.37 IL1B TNF
28 negative regulation of lipid catabolic process GO:0050995 9.13 IL1B INS TNF
29 MAPK cascade GO:0000165 9.02 CSF2 HGF IL1B INS TNF

Molecular functions related to Burns according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.33 CSF2 IL1B TNF
2 hormone activity GO:0005179 9.13 CRH INS TTR
3 protease binding GO:0002020 8.8 INS SERPINC1 TNF

Sources for Burns

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....